as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹475.0
Change
+0.95 (0.2%)
Open
₹475.9
Prev. Close
₹474.05
Day High
₹481.05
Day Low
₹470.0
Volume Analysis
Traded
361,831
Delivered
139,346
Delivery %
38.51%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Promoter holding is rising
Weaknesses (0)
No signal for this stock
Opportunities (1)
- •Strong 3-year revenue growth (19.3%)
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹491.75 | ₹486.4 | ₹480.7 | ₹475.35 | ₹469.65 | ₹464.3 | ₹458.6 |
| Fibonacci | ₹486.4 | ₹482.18 | ₹479.57 | ₹475.35 | ₹471.13 | ₹468.52 | ₹464.3 |
| Camarilla | ₹478.04 | ₹477.03 | ₹476.01 | ₹475.35 | ₹473.99 | ₹472.97 | ₹471.96 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+51.54%
1 Week
+1.82%
1 Month
+33.6%
3 Months
+15.14%
6 Months
+20.94%
1 Year
+88.73%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹143.38
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
12.85%
Net margin 11.36% × asset turnover 0.65x × equity multiplier 1.74x
Company Overview
Sector
Healthcare
Market Cap
₹4,448 Cr
P/E (TTM)
43.4
ROE
14.3%
Book Value
₹83.9
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 27 Sep 2026. Not investment advice.
TopFund Analysis
Sms Pharmaceuticals Ltd. lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 58/100. The strongest factor is Momentum (93/100), while Cash Flow (16/100) is the weakest area to weigh before deciding. Notably: Promoter holding is rising. Strong 3-year revenue growth (19.3%).
TopFund Score — Fundamentals Quality
58/100 — AverageData confidence: 78/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- −Stock is trading at 5.66 times its book value
- −Company has a low return on equity of 12.3% over last 3 years.
- −Company might be capitalizing the interest cost
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
38th AGM on 29 Sep 2026; annual report dispatched; proposed dividend Rs 0.40 per share.
SMS Pharmaceuticals filed BRSR for FY 2025-26, detailing ESG policies, workforce, compliance and sustainability initiatives.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 135 | 167 | 161 | 246 | 164 | 197 | 173 | 248 | 196 | 242 | 210 | 238 | 207 |
| Expenses + | 109 | 139 | 132 | 212 | 131 | 165 | 140 | 207 | 157 | 194 | 167 | 198 | 166 |
| Operating Profit | 26 | 28 | 29 | 34 | 34 | 31 | 33 | 41 | 39 | 48 | 44 | 40 | 41 |
| OPM % | 19.0% | 17.0% | 18.0% | 14.0% | 20.0% | 16.0% | 19.0% | 16.0% | 20.0% | 20.0% | 21.0% | 17.0% | 20.0% |
| Other Income + | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 4 | 3 | 2 |
| Interest | 6 | 6 | 6 | 6 | 5 | 5 | 4 | 5 | 6 | 6 | 6 | 5 | 6 |
| Depreciation | 8 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 10 |
| Profit before tax | 13 | 15 | 17 | 22 | 22 | 20 | 22 | 29 | 24 | 34 | 31 | 27 | 27 |
| Tax % | 31.0% | 21.0% | 26.0% | 26.0% | 25.0% | 29.0% | 24.0% | 30.0% | 23.0% | 26.0% | 26.0% | 23.0% | 26.0% |
| Net Profit + | 9 | 12 | 11 | 17 | 16 | 14 | 18 | 20 | 20 | 25 | 23 | 33 | 21 |
| EPS in Rs | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 2 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2007 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 193 | 611 | 438 | 463 | 465 | 412 | 563 | 520 | 522 | 709 | 783 | 887 | 898 |
| Expenses + | 145 | 522 | 363 | 369 | 375 | 332 | 442 | 405 | 467 | 593 | 644 | 716 | 725 |
| Operating Profit | 47 | 89 | 75 | 93 | 90 | 80 | 121 | 115 | 55 | 117 | 139 | 171 | 173 |
| OPM % | 25.0% | 15.0% | 17.0% | 20.0% | 19.0% | 19.0% | 22.0% | 22.0% | 10.0% | 16.0% | 18.0% | 19.0% | 19.0% |
| Other Income + | 5 | 4 | 1 | 2 | 3 | 5 | 3 | 5 | 5 | 4 | 6 | 8 | 9 |
| Interest | 8 | 17 | 16 | 15 | 12 | 12 | 11 | 19 | 22 | 24 | 19 | 23 | 23 |
| Depreciation | 5 | 19 | 19 | 20 | 19 | 22 | 22 | 32 | 32 | 32 | 34 | 40 | 40 |
| Profit before tax | 40 | 56 | 42 | 60 | 62 | 51 | 91 | 68 | 5 | 66 | 92 | 117 | 119 |
| Tax % | 36.0% | 26.0% | 14.0% | 33.0% | 34.0% | 36.0% | 33.0% | 1.0% | 28.0% | 26.0% | 27.0% | 25.0% | — |
| Net Profit + | 25 | 41 | 28 | 32 | 40 | 32 | 63 | 62 | -7 | 50 | 69 | 102 | 102 |
| EPS in Rs | 3 | 5 | 3 | 4 | 5 | 4 | 7 | 7 | -1 | 6 | 8 | 11 | 11 |
| Dividend Payout % | 8.0% | 4.0% | 6.0% | 7.0% | 5.0% | 7.0% | 4.0% | 4.0% | -36.0% | 7.0% | 5.0% | 4.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2007 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 182 | 285 | 246 | 276 | 313 | 340 | 402 | 462 | 452 | 528 | 631 | 776 |
| Borrowings + | 73 | 204 | 149 | 146 | 144 | 157 | 255 | 263 | 254 | 281 | 311 | 365 |
| Other Liabilities + | 64 | 158 | 89 | 72 | 93 | 103 | 147 | 126 | 165 | 217 | 202 | 212 |
| Total Liabilities | 329 | 656 | 493 | 503 | 559 | 608 | 812 | 860 | 880 | 1,034 | 1,153 | 1,362 |
| Fixed Assets + | 69 | 370 | 290 | 279 | 281 | 280 | 457 | 438 | 412 | 437 | 533 | 534 |
| CWIP | 15 | 13 | 8 | 8 | 18 | 42 | 7 | 11 | 33 | 30 | 35 | 122 |
| Investments | 0 | 21 | 29 | 28 | 27 | 26 | 27 | 22 | 11 | 11 | 12 | 26 |
| Other Assets + | 245 | 252 | 166 | 187 | 232 | 259 | 321 | 389 | 424 | 556 | 573 | 681 |
| Total Assets | 329 | 656 | 493 | 503 | 559 | 608 | 812 | 860 | 880 | 1,034 | 1,153 | 1,362 |
| Equity Capital | 10 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 9 | 9 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2007 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 14 | 61 | 73 | 32 | 50 | 40 | 90 | 45 | 22 | 50 | 82 | 59 |
| Cash from Investing Activity + | -32 | -97 | -39 | -17 | -35 | -43 | -152 | -27 | -30 | -52 | -123 | -131 |
| Cash from Financing Activity + | 107 | 27 | -33 | -15 | -13 | -2 | 92 | -12 | -32 | 31 | 47 | 76 |
| Net Cash Flow | 89 | -9 | 1 | 0 | 2 | -5 | 31 | 6 | -39 | 29 | 5 | 4 |
| CFO/OP | 42 | 93 | 110 | 46 | 70 | 65 | 88 | 52 | 50 | 56 | 73 | 49 |
| Free Cash Flow | -5 | -27 | 50 | 23 | 15 | -3 | -61 | 18 | -7 | -2 | -42 | -71 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 35.07% | 35.1% | 33.18% | 33.03% | 32.27% | 32.47% | 31.23% | 30.68% | 28.77% | 28.69% | 28.6% | 28.45% |
| Promoters | 64.32% | 64.32% | 64.67% | 64.67% | 64.67% | 64.67% | 66.27% | 66.27% | 68.07% | 68.07% | 68.07% | 68.07% |
| FII | 0.6% | 0.59% | 0.17% | 0.18% | 0.52% | 0.31% | 0.08% | 0.03% | 0.28% | 0.04% | 0.31% | 0.65% |
| DII | 0.0% | 0.0% | 1.98% | 2.13% | 2.55% | 2.55% | 2.43% | 3.03% | 2.88% | 3.21% | 3.02% | 2.83% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Sms Pharmaceuticals Ltd. (this stock) | 4,448 | 43.4 | 5.66 | 14.3% |
| Zota Health Care Limited | 4,629 | — | 6.69 | -15.0% |
| Gufic Biosciences Ltd. | 4,237 | 57.7 | 6.37 | 10.1% |
| Aarti Drugs Ltd. | 3,991 | 20.7 | 2.57 | 13.4% |
| Unichem Laboratories Ltd | 3,870 | 31.7 | 1.42 | 3.17% |
| Rpg Life Sciences Ltd | 5,045 | 43.2 | 8.34 | 19.3% |
| Kwality Pharmaceuticals L | 3,824 | 46.8 | 11.48 | 22.6% |
Which Mutual Funds Hold Sms Pharmaceuticals Ltd.?
Frequently Asked Questions about Sms Pharmaceuticals Ltd.
Sms Pharmaceuticals Ltd. (SMSPHARMA) closed at ₹475.0 on NSE on 25 September 2026, up 0.95 (0.2%) from the previous close.
Sms Pharmaceuticals Ltd. trades on the NSE (National Stock Exchange of India) under the symbol SMSPHARMA.
Sms Pharmaceuticals Ltd. has a trailing twelve-month P/E (price-to-earnings) ratio of 43.4.
Sms Pharmaceuticals Ltd. has a dividend yield of 0.08%.
Sms Pharmaceuticals Ltd.'s 52-week high is ₹494.0 and its 52-week low is ₹240.0.
Sms Pharmaceuticals Ltd. has a market capitalisation of ₹4,448 crore.
Sms Pharmaceuticals Ltd. has a TopFund Quality Score of 58/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Sms Pharmaceuticals Ltd.?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.